<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999128</url>
  </required_header>
  <id_info>
    <org_study_id>GDC4740g</org_study_id>
    <nct_id>NCT00999128</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers</brief_title>
  <official_title>An Open-Label, Two-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase I, randomized, two-part, single-center pharmacokinetics (PK) study to assess&#xD;
      the relative bioavailability of capsule and tablet formulations of GDC-0941 in the fasted&#xD;
      state (Part 1) and to determine the effect of food and proton pump inhibition on the PK of&#xD;
      the tablet formulation of GDC-0941 (Part 2). Approximately 18 subjects will be enrolled in&#xD;
      Part 1 and up to 32 subjects will be enrolled in Part 2. Subjects who participate in Part 1&#xD;
      are not eligible to participate in Part 2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 26, 2009</start_date>
  <completion_date type="Actual">February 26, 2010</completion_date>
  <primary_completion_date type="Actual">February 26, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, nature, and severity of adverse events</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of GDC-0941 (total exposure, maximum and minimum plasma concentration)</measure>
    <time_frame>Following administration of study drug</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0941</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rabeprazole</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male or female, between 18 and 65 years of age, inclusive (Part 1 only)&#xD;
&#xD;
          -  Male or female, between 18 and 45 years of age, inclusive (Part 2 only)&#xD;
&#xD;
          -  In good health, as determined by no clinically significant findings from medical&#xD;
             history, 12-lead electrocardiogram (ECG), and vital signs assessment&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18-30 kg/m^2 inclusive, with a body weight &gt;50 kg&#xD;
&#xD;
          -  Clinical laboratory evaluations within the reference range for the test laboratory&#xD;
&#xD;
          -  Negative test for selected drugs of abuse at screening (does not include alcohol) and&#xD;
             at check-in (does include alcohol)&#xD;
&#xD;
          -  Negative HIV, hepatitis B surface antigen (HBsAg), and hepatitis C virus antibody&#xD;
             screens&#xD;
&#xD;
          -  Agreement to use an effective form of contraception for the duration of the study&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  History or clinical manifestations of significant metabolic (including type 1 and 2&#xD;
             diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, endocrine,&#xD;
             gastrointestinal, urological, neurological, psychiatric disorders, or cancer&#xD;
&#xD;
          -  History of inflammatory arthritis&#xD;
&#xD;
          -  History of symptomatic hypotension&#xD;
&#xD;
          -  History of severe physical injury, direct impact trauma, or neurological trauma within&#xD;
             a specified timeframe prior to Day 1&#xD;
&#xD;
          -  History of seizure disorders&#xD;
&#xD;
          -  History of bipolar or major depressive disorder&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs (exceptions: appendectomy,&#xD;
             hernia repair, and/or cholecystectomy)&#xD;
&#xD;
          -  History or presence of an abnormal ECG&#xD;
&#xD;
          -  Subjects with a history of ventricular dysrhythmias or with risk factors for&#xD;
             ventricular dysrhythmias&#xD;
&#xD;
          -  History of alcoholism, drug abuse, or drug addiction&#xD;
&#xD;
          -  Use of any nicotine-containing or nicotine-replacement products within a specified&#xD;
             timeframe prior to Day 1&#xD;
&#xD;
          -  Participation in any other investigational study drug trial in which receipt of an&#xD;
             investigational study drug occurred within a specified timeframe prior to Day 1&#xD;
&#xD;
          -  Use of any prescription medications/products within a specified timeframe prior to Day&#xD;
             1 (exceptions: hormone replacement therapy [HRT], oral, implantable, or transdermal&#xD;
             contraception)&#xD;
&#xD;
          -  Receipt of any vaccination or immunization within a specified timeframe prior to Day 1&#xD;
&#xD;
          -  Use of proton pump inhibitors or H2-receptor antagonists within a specified timeframe&#xD;
             prior to Day 1&#xD;
&#xD;
          -  Known hypersensitivity to rabeprazole or any of its components, or to derived products&#xD;
             of benzimidazoles&#xD;
&#xD;
          -  Use of any over-the-counter (OTC), non-prescription preparations within a specified&#xD;
             timeframe prior to Day 1&#xD;
&#xD;
          -  Use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or&#xD;
             beverages within a specified timeframe prior to Day 1&#xD;
&#xD;
          -  Poor peripheral venous access&#xD;
&#xD;
          -  Donation of blood or plasma within a specified timeframe prior to Day 1&#xD;
&#xD;
          -  Receipt of blood products within a specified timeframe prior to Day 1&#xD;
&#xD;
          -  Vegetarians who are unable to consume a high-fat meal&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Holden, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Genentech Trial Information Support</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>October 19, 2009</study_first_submitted>
  <study_first_submitted_qc>October 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2009</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PI3K inhibitor</keyword>
  <keyword>PI3 kinase</keyword>
  <keyword>PI3 kinase inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

